Ipsen completes acquisition of Memo Therapeutics held by Schroders innovation trust

Ipsen completed the acquisition of Memo Therapeutics, a Schroders Capital Global Innovation Trust portfolio company, for €200m upfront and contingent payments which could raise total consideration above €700m. The sums are whole-company consideration, not Schroders direct proceeds.